Yasushi Iwasaki

Prof. Yasushi Iwasaki

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2016 in Neuropathology
Verified
Journal Article
Closed access
PDF file
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki

18 July 2006 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
MYMari Yoshida
Mari Yoshida
YHYoshio Hashizume
Yoshio Hashizume
TKTetsuyuki Kitamoto
Tetsuyuki Kitamoto
GSGen Sobue
Gen Sobue

3 June 2005 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
YHYoshio Hashizume
Yoshio Hashizume
MYMari Yoshida
Mari Yoshida
TKTetsuyuki Kitamoto
Tetsuyuki Kitamoto
GSGen Sobue
Gen Sobue

13 November 2013 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
AKAtsushi Kobayashi
Atsushi Kobayashi
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
HOHiroyuki Otsuka
Hiroyuki Otsuka
MYMasahito Yamada
Masahito Yamada
MYMari Yoshida
Mari Yoshida
TKTetsuyuki Kitamoto
Tetsuyuki Kitamoto
Sporadic Creutzfeldt-Jakob disease is classified according to the genotype at polymorphic codon 129 (M or V) of the prion protein (PrP) gene and the type (1 or 2) of abnormal isoform of PrP (PrPSc) in the brain. The most complicated entity in the current classification system is MV2, since it shows wide phenotypic variations, i.e., MV2 cortical form (MV2C), MV2 with kuru plaques (MV2K), or a mixed form (MV2K + C). To resolve their complicated pathogenesis, we performed a comprehensive analysis of the three MV2 subgroups based on histopathological, molecular, and transmission properties. In histopathological and molecular analyses, MV2C showed close similarity to MM2 cortical form (MM2C) and could be easily discriminated from the other MV2 subgroups. By contrast, MV2K and MV2K + C showed the same molecular type and the same transmission type, and the sole difference between MV2K and MV2K + C was the presence of cortical pathology characteristic of MV2C/MM2C. The remarkable molecular feature of MV2K or MV2K + C was a mixture of type 2 PrPSc and intermediate type PrPSc, which shows intermediate electrophoretic mobility between types 1 and 2 PrPSc. Modeling experiments using PrP-humanized mice indicated that MV2K contains a mixture of intermediate type PrPSc with the 129M genotype (Mi PrPSc) and type 2 PrPSc with the 129V genotype (V2 PrPSc) that originated from V2 PrPSc, whereas MV2C + K may also contain type 2 PrPSc with the 129M genotype and cortical pathology (M2C PrPSc) that lacks infectivity to the PrP-humanized mice in addition to Mi and V2 PrPSc. Taken together, the present study suggests that the phenotypic heterogeneity of MV2 stems from their different PrPSc origin(s).

16 January 2013 in Neuropathology
Verified
Journal Article
Closed access
PDF file
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
KMKeiko Mori
Keiko Mori
MIMasumi Ito
Masumi Ito
STShinsui Tatsumi
Shinsui Tatsumi
MMMaya Mimuro
Maya Mimuro
MYMari Yoshida
Mari Yoshida

12 November 2021 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
KSKazunori Sano
Kazunori Sano
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
YYYuta Yamashita
Yuta Yamashita
KIKeiichi Irie
Keiichi Irie
MHMasato Hosokawa
Masato Hosokawa
KMKenichi Mishima
Kenichi Mishima
Serine 129 (S129) phosphorylation of α-synuclein (αSyn) is a central feature of Lewy body (LB) disease pathology. Although the neighboring tyrosine residues Y125, Y133, and Y136 are also phosphorylation sites, little is known regarding potential roles of phosphorylation cross-talk between these sites and its involvement in the pathogenesis of LB disease. Here, we found that αSyn aggregates are predominantly phosphorylated at Y136 in the Lewy body dementia brain, which is mediated by unexpected kinase activity of Casein kinase 2 (CK2). Aggregate formation with S129 and Y136 phosphorylation of recombinant αSyn (r-αSyn) were induced by CK2 but abolished by replacement of S129 with alanine (S129A) in vitro. Mutation of Y136 to alanine (Y136A) promoted aggregate formation and S129 phosphorylation of r-αSyn by CK2 in vitro. Introduction of Y136A r-αSyn oligomers into cultured cells exhibited increased levels of aggregates with S129 phosphorylation compared to wild-type r-αSyn oligomers. In addition, aggregate formation with S129 phosphorylation induced by introduction of wild-type r-αSyn oligomers was significantly attenuated by CK2 inhibition, which resulted in an unexpected increase in Y136 phosphorylation in cultured cells. Our findings suggest the involvement of CK2-related αSyn Y136 phosphorylation in the pathogenesis of LB disease and its potential as a therapeutic target.